Table of Contents
ISRN Rheumatology
Volume 2012, Article ID 415272, 4 pages
Clinical Study

Anti-Ro52 Antibodies and Interstitial Lung Disease in Connective Tissue Diseases Excluding Scleroderma

1Unidade de Imunologia Clínica, Hospital de Santo António, Centro Hospitalar do Porto, 4099-001 Porto, Portugal
2Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal

Received 22 December 2011; Accepted 29 January 2012

Academic Editors: H. Ihn and C. G. Mackworth-Young

Copyright © 2012 João Pedro Ferreira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. The presence of anti-Ro52 antibodies has been reported in a wide variety of autoimmune diseases, particularly in myositis, scleroderma, and autoimmune liver diseases. Clinical significance of anti-Ro52 antibodies remains controversial, and studies are lacking for clarifying the association of anti-Ro52 with interstitial lung disease (ILD) in connective tissue diseases (CTD). Objectives. To determine if anti-Ro52 antibodies are associated with ILD in CTD other than scleroderma. Methods. Single-center, retrospective study based on immunoblotting panel analysis and patients clinical records. Results. In our connective tissue disease cohort, 162 patients had immunoblotting panels with anti-Ro52 reactivity analysis, 41 (25,3%) had inclusion criteria. Among the 41 selected sera, 85.4% ( 𝑛 = 3 5 ) had anti-Ro52 reactivity. The prevalence of ILD in the positive anti-Ro52 antibodies was 71.4% ( 𝑛 = 2 5 ), and 16.7% ( 𝑛 = 1 ) in the negative anti-Ro52 group ( 𝑃 = 0 . 0 1 8 ). Overall sensitivity (96.2%), specificity (83.3%), positive (71.4%) and negative (83.3%) predictive values of anti-Ro52 antibodies to determine ILD in CTD is detailed in this study. Conclusion. Ro52 autoantibodies are associated with ILD in CTD excluding scleroderma. We suggest that the presence of anti-Ro52 reactivity in CTD should increase the clinician curiosity for the search of ILD.